– USA, FL – Anju Software today announced the appointment of Steve Rosenberg to its Board of Directors, bringing a real-world clinical study perspective that will help align the strengths of Anju’s business segments with the industry’s continuing and evolving needs.
About Steve Rosenberg
Steve Rosenberg is a current board member at uMotif and recently accepted a role as their new CEO. uMotif is an eClinical platform for capturing patient-centric data in clinical trials. He has a more than four-decade career in positions where he has helped shape clinical study technology development, including cloud-based solutions with a more integrated approach to patient-centric trial management.
Steve Rosenberg designed the industry groundbreaking integrated clinical technology suite at Phase Forward, which Oracle acquired in 2010. Soon after, he led the growth of Oracle’s Health Sciences business, where he served most recently as its SVP and GM. Rosenberg is also a co-founder of The One By One project, a non-profit that helps people in need in the Boston area.
“Anju has a strong modern technology platform and significant experience in working with a wide range of Pharma and CROs globally,” said Steve Rosenberg. ” I look forward to helping Anju develop new solutions that will help optimize how and where to conduct trials using insights from data that is collected and analyzed.”
About Anju Software
Anju Software provides an adaptive platform for clinical trials, medical affairs, and a newly designed, state-of-the-art clinical content and data repository. Its AI-based analytical solution, combined with data and application integration capabilities, serves the worldwide pharmaceutical, biotech, and contract research organization markets.
For more information: https://www.anjusoftware.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.